case_images: PMC7071810_01
case_images: Clinical time course for a non-small-cell lung cancer patient treated with trastuzumab. The time course for disease and treatment and the results of performed genetic testing are shown starting from the time of diagnosis. Abbreviations: NGS: next-generation sequencing; WBRT: whole brain radiotherapy.
case_images: CRIONM2020-9072173.001.jpg
case_images: PMC7071810_01_CRIONM2020-9072173.001.jpg
case_images: fig1
case_images: The time course of his disease starting from diagnosis and his treatment is displayed in Figure 1.
case_images: Copy number profile of non-small-cell lung cancer tumor sample identifies ERBB2 amplification as a potentially actionable alteration. A tumor sample from the patient's lung was used to perform comprehensive genomic profiling. The resulting copy number profile is shown, with observed copy numbers being displayed on the y-axis. The red circle indicates the amplification of a genomic region that includes the ERBB2 gene.
case_images: CRIONM2020-9072173.002.jpg
case_images: PMC7071810_01_CRIONM2020-9072173.002.jpg
case_images: fig2
case_images: This amplification included CDK12, PGAP3, and the clinically relevant gene ERBB2 (Figure 2). The observed copy numbers for those genes were 11.5, 15, and 15, respectively.
case_images: Lung imaging results during the course of the disease. Chest CT imaging is shown for the time between October 2016 and October 2017. For the October 2016 CT image, the lesion is indicated by an arrow.
case_images: CRIONM2020-9072173.003.jpg
case_images: PMC7071810_01_CRIONM2020-9072173.003.jpg
case_images: fig3
case_images: CT imaging in June 2017 demonstrated a necrotic regression of the right upper lobe lung lesion after the initiation of trastuzumab treatment (Figure 3).